BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 7333912)

  • 1. The value of adjuvant misonidazole in the definitive irradiation of advanced head and neck squamous cancer: an RTOG pilot study (#78-02).
    Fazekas JT; Goodman RL; McLean CJ
    Int J Radiat Oncol Biol Phys; 1981 Dec; 7(12):1703-8. PubMed ID: 7333912
    [No Abstract]   [Full Text] [Related]  

  • 2. A report on misonidazole in randomized trial in locally advanced head and neck cancer.
    Sealy R; Williams A; Cridland S; Stratford M; Minchinton A; Hallet C
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):339-42. PubMed ID: 7050035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pilot study of radiotherapy with misonidazole in head and neck cancer.
    Paterson IC; Dawes PJ; Henk JM; Moore JL
    Clin Radiol; 1981 Mar; 32(2):225-9. PubMed ID: 7214840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A study of the effect of misonidazole in conjunction with radiotherapy for the treatment of head and neck cancer. MRC working party on misonidazole in head and neck cancer.
    Br J Radiol; 1984 Jul; 57(679):585-95. PubMed ID: 6329395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The treatment of locally advanced head and neck cancer with misonidazole, hyperbaric oxygen and irradiation: an interim report.
    Sealy R; Cridland S
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1721-3. PubMed ID: 6384161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The feasibility of high-dose multiple daily fractionation and its combination with anoxic cell sensitizers in the treatment of head and neck cancer. A pilot study of the Radiotherapy Group of the EORTC (European Organisation for Research on Treatment of Cancer).
    Van den Bogaert W; van der Schueren E; Horiot JC; Chaplain G; Arcangeli G; Gonzalez D; Svoboda V
    Int J Radiat Oncol Biol Phys; 1982 Oct; 8(10):1649-55. PubMed ID: 7153077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I/II study of the hypoxic cell sensitizer misonidazole as an adjunct to high fractional dose radiotherapy in patients with unresectable squamous cell carcinoma of the head and neck: a RTOG randomized study (#79-04).
    Lee DJ; Pajak TF; Stetz J; Order SE; Weissberg JB; Fischer JJ
    Int J Radiat Oncol Biol Phys; 1989 Feb; 16(2):465-70. PubMed ID: 2646255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced fractionation and the potential of hypoxic cell sensitizers in irradiation of malignant epithelial tumors.
    Cox JD; Byhardt RW; Komaki R; Greenberg M
    Int J Radiat Oncol Biol Phys; 1980 Jan; 6(1):37-40. PubMed ID: 6245044
    [No Abstract]   [Full Text] [Related]  

  • 9. Hyperfractionated radiotherapy with or without misonidazole: results of a prospective randomized study in stage III-IV squamous cell carcinoma of the head and neck.
    Panis X; Nguyen TD; Froissart D; Demange L
    Int J Radiat Oncol Biol Phys; 1984 Oct; 10(10):1845-9. PubMed ID: 6386760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Failure of misonidazole-sensitized radiotherapy to impact upon outcome among stage III-IV squamous cancers of the head and neck.
    Fazekas J; Pajak TF; Wasserman T; Marcial V; Davis L; Kramer S; Rotman M; Stetz J
    Int J Radiat Oncol Biol Phys; 1987 Aug; 13(8):1155-60. PubMed ID: 3301758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The treatment of squamous cell carcinoma of the head and neck with methotrexate and irradiation.
    Friedman M; Daly JF
    Am J Roentgenol Radium Ther Nucl Med; 1967 Feb; 99(2):289-301. PubMed ID: 6020797
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of hemoglobin concentration in the outcome of misonidazole-sensitized radiotherapy of head and neck cancers: based on RTOG trial #79-15.
    Fazekas JT; Scott C; Marcial V; Davis LW; Wasserman T; Cooper JS
    Int J Radiat Oncol Biol Phys; 1989 Dec; 17(6):1177-81. PubMed ID: 2689395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trials of misonidazole in the United States.
    Wasserman TH; Stetz J; Phillips TL
    Cancer Clin Trials; 1981; 4(1):7-16. PubMed ID: 7214664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Misonidazole and unconventional radiation in advanced squamous cell carcinoma of the esophagus: a phase II study of the Radiation Therapy Oncology Group.
    Ydrach AA; Marcial VA; Parsons J; Concannon J; Asbell SO; George F
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):357-9. PubMed ID: 6809704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of misonidazole in association with a three-fractions per day regimen in advanced head and neck epidermoid cancer. A pilot study.
    Awwad HK; Barsoum M; El Merzabani M; Omar S; El Badawy S; Ezzat S; El Baki HA; Zaki A
    Am J Clin Oncol; 1983 Feb; 6(1):91-7. PubMed ID: 6301258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of four cisplatin-based radiochemotherapy regimens for nonmetastatic stage III/IV squamous cell carcinoma of the head and neck.
    Rades D; Kronemann S; Meyners T; Bohlen G; Tribius S; Kazic N; Schroeder U; Hakim SG; Schild SE; Dunst J
    Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1037-44. PubMed ID: 20638185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irradiation with misonidazole and hyperbaric oxygen: final report on a randomized trial in advanced head and neck cancer.
    Sealy R; Cridland S; Barry L; Norris R
    Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1343-6. PubMed ID: 3531113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unorthodox radiotherapy in advanced neoplasms of the head and neck.
    Hannemann JH
    J Maine Med Assoc; 1975 Apr; 66(4):97-101 103. PubMed ID: 1127350
    [No Abstract]   [Full Text] [Related]  

  • 19. Adjuvant intravenous methotrexate or definitive radiotherapy alone for advanced squamous cancers of the oral cavity, oropharynx, supraglottic larynx or hypopharynx.
    Fazekas JT; Sommer C; Kramer S
    Int J Radiat Oncol Biol Phys; 1980 May; 6(5):533-41. PubMed ID: 7410127
    [No Abstract]   [Full Text] [Related]  

  • 20. Late results of multiple fractions per day (MFD) with misonidazole in advanced cancer of the head and neck. A pilot study of the EORTC radiotherapy group.
    Van den Bogaert W; van der Schueren E; Van Tongelen C; Horiot JC; Chaplain G; Arcangeli G; Gonzalez D; Svoboda V
    Radiother Oncol; 1985 Feb; 3(2):139-44. PubMed ID: 3983422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.